8-K: Current report filing
Published on March 3, 2003
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (date of earliest event reported): February 27, 2003
COMMONWEALTH BIOTECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
| Virginia |
001-13467 |
56-1641133 |
||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
601 Biotech Drive
Richmond, Virginia 23235
(Address of principal executive offices)
Registrants telephone number, including area code: (804) 648-3820
| ITEM 7. | FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS |
| (a) | Financial statements of businesses acquired. |
N/A
| (b) | Pro forma financial information. |
N/A
| (c) | Exhibits. |
| 99.1 | Press release, dated February 27, 2003, relating to the registrants receipt of notification from the Nasdaq SmallCap Market of the registrants satisfaction of Nasdaqs minimum bid price rule. (Marketplace Rule 4310 (c)(8)(D)) |
2
Pursuant to the requirement of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| COMMONWEALTH BIOTECHNOLOGIES, INC. |
||
| By: |
/s/ Robert B. Harris, Ph.D. |
|
| Robert B. Harris, Ph.D. President and Chief Executive Officer |
||
Dated: March 3, 2003
3
EXHIBIT INDEX
| Number |
Description of Exhibit |
|
| 99.1 |
Press release, dated February 27, 2003, relating to the registrants receipt of notification from the Nasdaq SmallCap Market of the registrants satisfaction of Nasdaqs minimum bid price rule. (Marketplace Rule 4310 (c)(8)(D)) |
4